My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX nasdaq
United States
Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Analysis & Ratings

Vertex Pharmaceuticals Stock Analysis Overview

Smart Score
7
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Vertex Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

VRTX

VRTX Stock Stats

Previous Close$180.8
Open$182.06
Bid184.5 x 10
Ask185.2 x 8
Today’s Range$181.11 - $185.5989
52-Week Range$176.36 - $242.99
Volume2.01M
Average Volume1.98M
Market Cap$48.10B
Beta0.66
P/E Ratio23.8
EPS7.59
Earnings DateOct 27, 2021

Company Description

Vertex Pharmaceuticals

Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Employees
3,400
ISIN
US92532F1003
Address
50 Northern Avenue, Boston, MA, 02210, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

Vertex Pharmaceuticals News


VRTX FAQ

What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $176.36 and its highest was $242.99 in the past 12 months.
    What is Vertex Pharmaceuticals’s market cap?
    Vertex Pharmaceuticals’s market cap is $48.10B.
      What is Vertex Pharmaceuticals’s price target?
      The average price target for Vertex Pharmaceuticals is $245.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $323.00 ,the lowest forecast is $175.00. The average price target represents 32.14% Increase from the current price of $185.41.
        What do analysts say about Vertex Pharmaceuticals?
        Vertex Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
          When is Vertex Pharmaceuticals’s upcoming earnings report date?
          Vertex Pharmaceuticals’s upcoming earnings report date is Oct 27, 2021 which is in 7 days.
            How were Vertex Pharmaceuticals’s earnings last quarter?
            Vertex Pharmaceuticals released its earnings results on Jul 29, 2021. The company reported $3.11 earnings per share for the quarter, beating the consensus estimate of $2.531 by $0.579.
              Is Vertex Pharmaceuticals overvalued?
              According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
                Does Vertex Pharmaceuticals pay dividends?
                Vertex Pharmaceuticals does not currently pay dividends.
                What is Vertex Pharmaceuticals’s EPS estimate?
                Vertex Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Vertex Pharmaceuticals have?
                Vertex Pharmaceuticals has 259,430,000 shares outstanding.
                  What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
                  Vertex Pharmaceuticals reported an EPS of $3.11 in its last earnings report, beating expectations of $2.531. Following the earnings report the stock price went down -0.326%.
                    Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
                    Among the largest hedge funds holding Vertex Pharmaceuticals’s share is ARK Investment Management LLC. It holds Vertex Pharmaceuticals’s shares valued at 358M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis